Roots Analysis has announced the addition of the “HDAC Inhibitors Market, 2016-2026” report to their list of offerings. It provides a comprehensive study on the current landscape of the evolving pipeline in this area. With five commercialized products, the market has gained the attention of several industry and non-industry players. The increasing popularity of HDAC inhibitors on social media validates the growing interest in this field.

Rohit Kumar, the principal analyst, said, “Amongst other elements, the report elaborates on novel class-specific HDAC inhibitors that are being developed and the upcoming opportunities in this market for different stakeholders. One of the key objectives outlined for this report was to understand the future potential of the market. This was done by analyzing:

• The HDAC inhibitors pipeline in terms of phase of development, type of products and target indications.
• The likely adoption of the HDAC inhibitors in the coming few years by understanding the competition posed by the current treatment regimens.
• Prevalent and emerging trends in the HDAC inhibitors domain highlighted on social media platforms, such as Twitter and Facebook.
• The ongoing research activity in this field, in terms of the focus of research articles published across the globe in the last two years.”

Kumar added, “Nearly 90 HDAC inhibitors are currently in clinical / preclinical stages of development; the clinical molecules account for over 30% of the pipeline while over 60% is captured by molecules in the preclinical / discovery stage. While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends that are emerging in the industry. Our opinions and insights, presented in this study, were influenced by several discussions conducted with experts in this area, including senior representatives at Karus Therapeutics, Mirati Therapeutics and the Yale School of Medicine.”

The 223 page report includes detailed profiles and an assessment of the HDAC inhibitor product candidates being developed by several players, such 

• 4SC
• Celgene Corporation
• Chroma Therapeutics
• Curis
• Evgen Pharma
• FORUM Pharmaceuticals
• Italfarmaco
• MEI Pharma
• Mirati Therapeutics
• Novartis
• Onxeo
• Pharmacyclics
• Shenzhen Chipscreen Biosciences
• Syndax Pharmaceuticals
• TetraLogic Pharmaceuticals

In addition, the report highlights several non-industry institutes and universities that are primarily carrying out preclinical research. Examples of these include Harvard Medical School (BG45), Imperial College London (C1A), Kyoto University (Jδ, Sδ), National Taiwan University (Quinazolin-4-one derivatives), Taipei Medical University (MPT0E028), University of Messina (MC-1575, MC-1568).

For additional details, please visit

https://www.rootsanalysis.com/reports/market-reports/view_document/hdac-inhibitors-market-2016-2026/137.html or email sales@rootsanalysis.com

About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at  info@rootsanalysis.com